Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its ...

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and ...